Reduction in itch after first dose (as measured at Week 3)
Significant itch reduction
(≥4-point improvement in
Worst Scratch/Itch NRS)
with DUPIXENT + TCS at
Week 16 in AD-1539
(secondary endpoint)1‑3,a,b
Definitive conclusions cannot be made for time points earlier than Week 16 as those data were not multiplicity controlled and P value was nominal.
aFull Analysis Set includes all subjects randomized.1
bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.1
EXPLORE MORE PEAK PRURITUS
NRS EFFICACY RESULTS
VIEW
ADULT DATA
VIEW ADOLESCENT
(12 TO 17 YEARS) DATA
VIEW CHILD
(6 TO 11 YEARS) DATA
Worst Scratch/Itch NRS assesses the average itch intensity over the previous 24 hours4
It is a patient-reported measure that uses a 0- to 10-point scale, with which caregivers of infants to preschoolers aged 6 months to 5 years were asked:
“How would you rate your child’s scratching/itching at its worst in the past 24 hours?”
0
None
1
2
3
4
5
6
7
8
9
10
The Worst
Imaginable
A reduction of at least 4 points in Worst Scratch/Itch from baseline is a clinically meaningful change.2
Dosage and
administration
Thinking about prescribing DUPIXENT?
Find the information you need to get started.